In the current study, we intratumorally injected IFN-β but not IFN-γ in vivo analysis because immunoadjuvants such as poly(I:C) and CpG are often used in clinical settings and mainly induce type I IFNs to enhance immune activity in cancer patients. Here, IFNG is linked to cancer.